Events

Online Consortia-Building event Health (Cluster 1) - 2024 two-stage calls
MAR
Thu
30
10:30 - 13:30

This was 2 years ago

Location

Online

Programmes
Health

The UK Horizon Europe Health National Contact Points (NCPs), together with the Innovate UK KTN Global Alliance, are organising an online consortia-building event for 2024 two-stage Health call topics (with proposal submission deadlines on 19 September 2023). 

The event is open to stakeholders from all countries interested in collaborating on the Horizon Europe Health two-stage call topics and ready to take the next steps, discussing concrete project ideas with potential partners and going forward to proposal submission.

Detailed information and the registration form are available on the event website. The registration deadline is on 28 March

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.